



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/686,491	10/14/2003	Rossella G. Tupler	07917-180001 / UMMC 03-18	3543
26161 7590 03/22/2007 FISH & RICHARDSON PC P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022			EXAMINER STANDLEY, STEVEN H	
			ART UNIT	PAPER NUMBER
			1649	

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	03/22/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

DETAILED ACTION

Election/Restrictions

1. Applicant's election with traverse of Group I, claims 1-7, and new claims 21-23 in the reply filed on 11/13/06 is acknowledged. Applicant further elected the species FRG1. The traversal is on the grounds that the generic claims to 4q35 region of chromosome 4 encompass the elected species. This is found persuasive.

The requirement is still deemed proper and is therefore made FINAL.

Priority

2. Priority is to the provisional application 60/418,024, filed 10/11/02.

Sequence Compliance

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and /or amino acid sequences set forth in 37 CFR 1821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 because 37 CFR 1.821 (a)(2)(c-d) states that each sequence disclosed must appear separately in the sequence listing and in the text of the description and claims whenever described. For example, a SEQ ID NO: and sequence listing is required for the nucleic acid sequence shown in Figure 2C of the drawings. For instance, the SEQ ID NO: may be referenced in the "Brief Description of Drawings." See MPEP 2422 & 2431. This is not meant to be an exhaustive list of places where the specification fails to comply with the sequence rules. The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may

Art Unit: 1649

become aware in the specification. The application cannot issue unless it is in compliance. Correction is required.

Information Disclosure Statement

3. The IDS' of 12/02/04 and 9/16/05 have been considered by the Examiner.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 1-7, 10-11 and 21-23 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for providing a D4Z4 binding element ***with a specific sequence*** localized in region 4q35 of human chromosome 4, contacting the D4Z4 binding element with a test compound and determining whether the test compound interacts with the D4Z4 binding element, does not reasonably provide enablement for providing "a D4Z4 binding element," contacting the D4Z4 binding element with a test compound and determining whether the test compound interacts with the D4Z4. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims. Further, the specification is not enabling for determining the level of expression of recited ***genes***, generic genes or named.

The factors considered when determining if the disclosure satisfies the enablement requirement and whether any necessary experimentation is "undue" include, but are not limited to:

1) nature of the invention, 2) state of the prior art, 3) relative skill of those in the art, 4) level of predictability in the art, 5) existence of working examples, 6) breadth of claims, 7) amount of direction or guidance by the inventor, and 8) quantity of experimentation needed to make or use the invention. In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

The invention is highly complex because it is not known just what constitutes "a D4Z4 binding element" from the specification or the prior art. The specification provides a circular, open-ended, structurally open definition on page 3, wherein "providing a D4Z4 binding element, e.g., DNA comprising one or more D4Z4 repeats," constitutes the only limitation to the DNA structure. Also, the specification teaches that, "D4Z4 is highly polymorphic with a variable number tandem repeat (VNTR) structure D4Z4." This definition imports little structural limitation to the D4Z4 binding element. Further, the specification discloses a 27 bp "minimal binding element." However, it is not known if the D4Z4 element comprises one or some defined number of **exact** repeats of this element, or whether this "minimal binding element" is loosely repeated in a D4Z4 binding element. It is not known from the specification what constitutes the structural limits of a D4Z4 binding element, nor what are the essential features of the D4z4 binding element. Therefore one skilled in the art would not recognize a D4Z4 binding element as recited in the claims and defined in the specification.

The prior art recognizes species variations in the sequences of the D4Z4 repeats (see Winokur et al., 1996), as well as D4Z4 repeats on all acrocentric chromosomes which include chromosomes 14, 15, 21 and 22. A blast analysis of a large fragment of the d4z4 repeat unit (accession D38024; appendix a; also see Lyle et al, 1995) shows divergence from the sequence in chromosome 10 (appendix b), indicating that 1) the

Art Unit: 1649

sequences are different, and 2) D4Z4 domains on the other acrosomal chromosomes listed above are divergent. Further, a blast of multiple copies of the “minimal binding element,” as it relates to claim 23 for instance, against human genomic sequence yielded no sequence homology to anything. Therefore, at best the art and the specification give only an open-ended definition of D4Z4 that lacks structural boundaries. The art and the specification recognize an open ended, wide range of deletions or rearrangements, or repeats as, as well as plainly describing it as a highly variable region. Furthermore, claims 2-7 are directed to a D4Z4 binding element in a cell that expresses 4Q35, which does not mean the D4Z4 element must be the one localized on 4q35. Thus, the method measures the binding to elements that have nothing to do with 4q35, and nothing to do with expression of genes in that region.

The art (in this case, post filing date) indicates many other genes in the region of 4q35 (Blair et al, 2005) than are described in the disclosure or in the prior art. See Table I, Blair et al. Thus, the specification could not have been enabling for a generic “4q35 gene” at the time of filing. The claims also recite measuring expression of FSHD region **genes**, such as FRG1, etc. However there is no description of such genes, their introns/exons, splice sites, promoter regions, and splice forms. Therefore one skilled in the art would not know what is being measured nor how to measure it.

Given the variance across species, the existence of multiple D4Z4 regions throughout the genome, and the lack of apparent homology to the putative minimal binding element, what constitutes a D4Z4 domain is highly unpredictable.

The breadth of the claims is such that they encompass D4Z4 regions unrecognizable to one skilled in the art.

Given the complex nature of the invention, the unpredictability of the art, the lack of adequate teachings or examples in the specification, and the breadth of the claims, one skilled in the art would not know how to make or use the invention as claimed.

5. Claims 1-7, 10-11 and 21-23 rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicant claims a method of identifying compounds by using a generic D4Z4 binding element, a generic 4q35 gene, and FRG1, FRG2, and ANT1 **genes**. However, the specification lacks a closed structural definition of such things. Moreover, these elements are not known in the art (as demonstrated above). One skilled in the art would not recognize such. No written description is provided in the instant specification as to what structurally constitutes nucleotide sequences "...comprising D4Z4 binding elements or 4q35 genes", the boundaries and functional elements of which would be unknown to one skilled in the art at the time the invention was made. The specification has not described, nor can it be reasonably visualized by one skilled in the art, the structural and functional elements attributable to chromosome 4, which represents the boundaries of the nucleotide sequences as currently claimed. For example,

Art Unit: 1649

chromosome 4 contains other undescribed promoters, coding regions, 5' and 3' flanking regions, exons and introns, each with their own unique structure and function that is not described in the instant specification. In short, a D4Z4 binding element and 4q35 region, as written, are readable on the whole of chromosome 4, as well as other chromosomes. FRG1, FRG2, and ANT1 **genes** have undescribed promoters, coding regions, 5' and 3' flanking regions, introns and exons, each with their own unique structure and function that is not described in the specification.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See *Vas-Cath* at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of structures claimed, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CMC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

Art Unit: 1649

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-2, and 7 are rejected under 35 U.S.C. 102(b) as being anticipated by Winokur et al (1996).

Winokur et al provides a D4Z4 binding element (which is in a human lymphoblast; Figure 1, page 1568), contacts that element with DNA that hybridizes to the end of chromosome 4 (cosmid 88F8), which is contiguous with the D4Z4 binding element (see Figure 1). Thus, the test compound (DNA) interacts with the D4Z4 binding element. Steps (a)-(c) are accomplished by Winokur et al. Step (d) imports no limitations on the compound selected (i.e., the compound could be any compound); and step (d) necessarily flows from step (c) when the compound interacts with D4Z4. In other words, step (d) is inherently accomplished with the practice of steps (a)-(C) because "selecting the test compound as a candidate..." is accomplished when it is determined that a test compound interacts with D4Z4.

Conclusion


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Steven Standley whose telephone number is **(571) 272-3432**. The examiner can normally be reached on Monday through Friday, 8:00 AM to 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on **(571) 272-0867**.


Art Unit: 1649

The fax number for the organization where this application or proceeding is assigned is **703-872-9306**.










Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at **866-217-9197** (toll-free).

Steve Standley, Ph.D.
1/25/07




DAVID S. ROMEO
PRIMARY EXAMINER

Appendix A

[PubMed](#)
[Nucleotide](#)
[Protein](#)
[Genome](#)
[Structure](#)
[PMC](#)
[Taxonomy](#)
[OMIM](#)
[Books](#)

Search for

[Limits](#)
[Preview/Index](#)
[History](#)
[Clipboard](#)
[Details](#)

Display Show Hide: ☐ Sequence ☐ Lesser features

Range: from to ☐ Reverse complemented strand Features:

1: [D38024](#). Reports Homo sapiens FSHD...[gi:871846]

[Links](#)

[Features](#) [Sequence](#)

LOCUS HUMFSHD 3303 bp DNA linear PRI 29-MAY-2002
 DEFINITION Homo sapiens FSHD gene for facioscapulohumeral muscular dystrophy, complete cds, 4Z4 tandem repeat unit.
 ACCESSION D38024
 VERSION D38024.1 GI:871846
 KEYWORDS .
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 3303)
 AUTHORS Lee, J.H., Goto, K., Matsuda, C. and Arahata, K.
 TITLE Characterization of a tandemly repeated 3.3-kb KpnI unit in the facioscapulohumeral muscular dystrophy (FSHD) gene region on chromosome 4q35
 JOURNAL Muscle Nerve 2, S6-S13 (1995)
 PUBMED 7739628
 REFERENCE 2 (bases 1 to 3303)
 AUTHORS Lee, J.
 TITLE Direct Submission
 JOURNAL Submitted (22-AUG-1994) Je Hyeon Lee, National Institute of Neuroscience, NCNP, Department of Neuromuscular Research; 4-1-1 Ogawa-higashi, Kodaira, Tokyo 187, Japan (Tel:0423-46-1712, Fax:0423-46-1742)
 FEATURES Location/Qualifiers
 source 1..3303
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /chromosome="4"
 /map="4q35-qter"
 /clone="c51"
 repeat_unit 1..3303
 /note="3303bps KpnI fragment in FSHD gene region contains other repeat and sequence motive"
 /function="unknown"
 /rpt_family="D4Z4"
 /rpt_type=tandem
 repeat_region 1..300
 /note="region with similarity to Lsau(GenBank X59423), Part of tandem repeat D4Z4"
 /function="unknown"

```

misc feature      /rpt_type=other
393..578
/note="extremly G-rich region in 186bps. Part of tandem
repeat locus D4Z4"
/function="unknown"
satellite         398..578
/note="microsatellite of GGAGG, Part of tantem repeat
locus D4Z4"
/rpt_type=direct
gene              417..2978
/gene="FSHD"
CDS               417..2978
/gene="FSHD"
/note="ORF"
/codon_start=1
/product="facioscapulohumeral muscular dystrophy"
/protein_id="BAA07227.1"
/db_xref="GI:1435038"
/translation="MERGTGETRGAEGTLGGRQGGREAGRNGGRDRATQGLGAGPREP
GTDGGRKAGRKSGPRPPGVAGPPASGKTVSVRRGLRAGPTAAAPAGGAPPPIRPGSGAQ
GVGGFLRDKRPGLGLPSGLHPRGSQTAHPQAEPCNAARGPQTRPRRSHTQDDGGVILV
SEWLCPPEGGLLLTSLRPPKGWPCRLFAPGALRHPETCREGCKPGMVPSLSLPGSKPA
TLQTPPRCRTRESIVRPSRRGGISSLSRSGLLRGNEREPHACVCETVPATATPTGIA
SFTERGPGTLKTPTEVQFHTPLHPPRLVSPCCRRVGAQRAASRSRGIPGEVRRAGPRN
APPSPLPPLPLPLRLSGPTTTTATTPPPPPPPPTTTTTTTTPPAGPRRRPGSLPGWGG
LSQGGSPPFMKGWSLPACGPLQGRLAGWLAVRAGLLAAPAAVHSPAIEVHGSPASLCP
RPSVKFRPGLTAMALPTPSDSTLPAEARGRGRPRRLVWTPSQSEALRACFERNPYPGI
ATRERLAQAIGIPEPRVQIWFQNERSRQLRQHRRESRPWPGRRGPPGERRKRTAVTGS
QTALLLRAFEKDRFPGIAAREELARETGLPESRIQIWFQNRARRHPGQGGRAQAAGG
LCSAAPGGGHPAPSWVFAHTGAWGTGLPAPHVPCAPGALPQGAFFVQAARAAPALQP
SQAAPAEVSVQAPARGDFAYAAPAPPEPGRSPTLRLLGGLRTRAKAGRTGTRSATAC
RAPARWHSGLGPLKGRRRPRGACATHVPGESVVGLGPGSPGRRGGVGTPSRGSSTSPAR
APGTPPPPRGRGRCKASRRPPRRSRSRPGLHSPAACCWMSSWRARSFCSRRNLS"

misc feature      1405..1554
/gene="FSHD"
/note="Extremly C-rich region(69%) in 186bps. Part of
tandem repeat locus 4DZ4."
/function="unknown"
satellite         1470..1536
/gene="FSHD"
/note="microsatellite of CCA, Part of tandem repeat locus
D4Z4"
/rpt_type=direct
satellite         1590..1703
/gene="FSHD"
/note="microsatellite of GGCT, Part of tandem repeat locus
D4Z4"
/rpt_type=direct
misc feature      1863..2037
/gene="FSHD"
/note="paired type homeodomain seq I,
translation;PRRLVWTPSQSEALRACFERNPYPGIATRERLAQAIGIPEPRVQIWFQNERSRQLR"
/function="unknown"
misc feature      2082..2264
/gene="FSHD"
/note="paired type homeodomain seq II,
translationGRRKRTAVTGSQTALLLRAFEKDRFPGIAAREELARETGLPESRIQIWFQNRARRHPGQG"
/function="unknown"

```

ORIGIN

```
1 ggtaccagca ggtgggcccgc ctactgcgca cgcgcggggtt tgcgggcagc cgcctgggct
61 gtgggagcag cccggggccag agctctcctg cctctccacc agcccacccc gccgcctgac
121 cgccccctcc ccacccccca cccccacccc ccggaacacg cgtcgtcccc tgggctgggt
181 ggagaccccc gtcccgcgaa acaccggggc ccgcgcagcg tccgggacct acaccgctcc
241 gccggctcgc ctctcctgt cgcctccggg ccaccgtcgc ccgcccgcgc gggcccctgc
301 gggcccctgc agccgcccag ctgccagcac gggcggtggt cggcggaacg cagaccccag
361 gcccggcgca caccggggac gctgagcggt ccaggcgga ggaaggcg gacagatgg
421 agagaggaa gggagagact agaggggcgg aaggagcgtt agggaggagg caggaggga
481 gggaggcagg gaggaacgga gggagagaca gagcgacgca gggactgggg gcggggccga
541 gggagccggg gacggacggg gggaggaagg caggaggaa aagcggtcct cggcctccgg
601 gaggtagcgg accgcccgc tccgggaaaa cggtcagcgt ccggcgcggg ctgagggctg
661 ggccacagc cgccgcgcgc gccggcgggg caccacccat tcgccccggg tccggggccc
721 agggagtgg cggtttctct cgggacaaaa gaccgggact cgggttgccg tcgggtcttc
781 acccgcgcgg ttcacagacc gcacatcccc aggtgagacc ctgcaacgcg gcgcgaggcc
841 cacagacccg gccacggagg agccacacgc aggacgacgg aggcgtgatt ttggtttccg
901 agtggtttt cctcccga ggcggcctgt tgctcacgtc tctccggccc ccgaaaggct
961 ggccatgccg actgtttgt cccggagctc tgcggcacc ggaacatgc agggagggt
1021 gcaagcccg catggtgct tcgtctcct tgcagggtc caaacccgc aactgcaga
1081 ctccccacg ttgcgcacg cgggaatcca tcgtcaggcc atcacgccc ggaggcatct
1141 cctctctgg gtctcgtct ggtcttctac gtggaaatga acgagagcca cagcctgag
1201 tgtgcgagac cgtcccggca acggcgacgc ccacaggcat tgctctctc acggagagag
1261 ggccctggc actcaagact ccacggagg ttcagttcca cactccctc caccctcca
1321 ggctggtttc tccctgctgc cgacgctgg gagccagag agcggttcc cgttcccg
1381 ggatccctgg agaggtcgg agagccggcc cccgaaacgc gccccctcc cccctcccc
1441 ctctccccct tctcttctg ctctccggcc ccaccaccac caccgccacc acgcctcccc
1501 caccaccccc cccccccacc accaccacca ccaccacccc gccggccggc ccaggcctc
1561 gacgccttg gtcccttcc ggggtggggc ggctgtccca ggggggctca ccgccattca
1621 tgaaggggtg gagcctgct gcctgtgggc ctttacaagg gcggtgggt gggtggctgg
1681 ctgtccgggc aggcctcct gctgcacct ccgcagtga cagtccggct gaggtgcacg
1741 ggagcccgc ggctctctc tgcccgctc cgtccgtgaa attccggcc gggtcaccg
1801 cgatggccct ccgacaccc tcggacagca cctccccgc ggaagcccg ggacgaggac
1861 ggccacggag actcgtttg accccgagcc aaagcgaggc cctgcgagcc tgctttgagc
1921 ggaacccgta cccgggcata gccaccagag aacggctggc ccaggccatc ggcattccgg
1981 agcccagggt ccagatttg tttcagaatg agaggtcac ccagctgagg cagcaccggc
2041 gggaaatctg gccctggccc gggagacgcg gcccgccaga aggcgggca aagcggaccg
2101 ccgtcaccgg atcccagacc gccctgctcc tcgagcctt tgagaaggat cgttttccag
2161 gcctgcggc ccgggaggag ctggccagag agacgggct cccggagtcc aggttcaga
2221 tctggtttca gaatcgaagg gccaggcacc cgggacaggg tggcaggggc cccgcgcagg
2281 caggcgccct gtgcagcgcg gccccggcg ggggtcacc tgctccctcg tgggtcgct
2341 tcgcccacac cggcgcggtg ggaacggggc ttcccgacc ccacgtgccc tgcgcgctg
2401 gggctctccc acagggggct ttcgtgagc aggcagcgag ggccgcccc gcgctgcagc
2461 ccagccaggc cgcgcgggca gagggggtct cccaacctgc cccggcgcg cgggatttcg
2521 cctacgcgc cccggtcct ccggagccgg ggcgtctcc caccctcagg ctctcggtg
2581 gcctcgcac ccgggcaaaa gccgggaggga ccgggacccg cagcgcgacg gcctgccggg
2641 cccctgcgc gtggcacagc ctgggcccgc tcaagcgggg ccgcaggcca aggggtgctt
2701 gcgccacca cgtcccagg gagtcggtg tggggtggg gccggggtcc ccaggtcgcc
2761 ggggcggcgt gggaaaccca agccggggca gctccacct cccagcccgc gccccggga
2821 cgcctccgc tccgcgcggc aggggcagat gcaaggcatc ccggcgccct cccaggcgct
2881 ccaggagccg gcgcctggt ctgactccc ctgcggcctg ctgctggatg agctcctggc
2941 gagcccgag tttctgcagc aggcgaacc tctcctagaa acggaggccc cgggggagct
3001 ggaggcctcg gaagaggcgc ctgctggaa gcaacctca gcgaggaaga ataccgggct
3061 ctgctggagg agcttttaga cgcggggtt ggacggggtc ggggtggttc gggcaggggc
3121 gtggcctctc tttcgcgggg aacacctggc tggtacgga gggcggtgc tccgccccgc
3181 cccctccacc gggctgacc gcctgggatt cctgccttct aggtccaggc ccggtgagag
3241 actccacacc gcggagaact gccattcttt cctgggcatc ccggggatcc cagagccggc
3301 cca
```

//

[Disclaimer](#) | [Write to the Help Desk](#)

Appendix B

> ☐ ref|NT_017795.18|Hs10_17951 ☒ Homo sapiens chromosome 10 genomic contig, referer
Length=1797220

Sort alignments for this su
E value Score Percent i
Query start position Sub

Features flanking this part of subject sequence:

226 bp at 5' side: similar to double homeobox 4c

1277 bp at 3' side: similar to double homeobox 4c

Score = 739 bits (384), Expect = 0.0
Identities = 513/555 (92%), Gaps = 35/555 (6%)
Strand=Plus/Plus

Query	1	ggtaccagcaggtgggcccgcctactgcgcacgcgcgggtttgcgggcagccgcctgggct	60
Sbjct	1751312	GGTACCAGCAGGTGGGCCGCCTACTGCGCACGCGCGGGTTTGCGGGCAGCCGCCTGGGCT	175137
Query	61	gtgggagcagcccgggccagagctctcctgcctctccaccagccaccccgccgcctgac	120
Sbjct	1751372	GTGGGAGCAGCCCGGGC-AGAGCTCTCCTGCCTCTCCACCAGCCACCCCGCCGCCTGAC	175143
Query	121	cgcacctccccacccccacccccaccccccgaaaaacgcgtcgctccctgggctgggt	180
Sbjct	1751431	CGCCCCCTCCCCACCCCC-ACCCCCCGCCCCGGAACGCGTCGTCCCTGGGCTGGGT	175148
Query	181	ggagacccccgtcccgcgaaacacggggcccgcgagcgtccgggctgacaccgctcc	240
Sbjct	1751490	GGAGACCCCGTCCCGCGAAACACCGGGCCCCGCGCAGCGTCCGGGCCTGACACCGCTCC	175154
Query	241	gcgggtcgccctctcctgtgcgccccggggccacgcgtcgcccgcccgccggggccctgc	300
Sbjct	1751550	GGCGGCTCGCTCTCTC-TG-CGCCCCGCGCCACCGTCGCCCCGCCCGCCGGGCCCCCTGC	175160
Query	301	gggccccctgcagccgcagctgccagcacgg-gcgggtggcgggcggaacgcagaccCA	359
Sbjct	1751608	-----AGCCGCCAGGTGCCAGCACGGAGCGCCTGGCGGCGGAACGCAGACCCCA	175165
Query	360	GGCCCGGCGCACACCGGGGACGCTGAGCGTTCCAGGCGGGAGGGAAGGCGGGCAGAGATG	419
Sbjct	1751658	GGCCCGGCGCACACCGGGGACGCTGAGCGTTCCAGGCGGGAGGGAAGGCGGGCAGAGATG	175171
Query	420	GAGAGAGGAACGGGAGAGACTAGAGGGGCGGA-----AGGGACGTTA-----	461
Sbjct	1751718	GAGAGAGGAACGGGAGA-CCTAGAGGGGCGGAAGGATGGGCGGAGGGACGTTAGGAGGGA	175177
Query	462	-GGAGGGAGGCAGGGAGGCAGGGAGGCAGGGAGGAACGGAGGGAGAGACAGAGCGACGCA	520
Sbjct	1751777	GGGAGGGAGGCAGGGAGGCAGGGAGGCAGGGAGGAACGGAGGGAAAGACAGAGCGACGCA	175183
Query	521	GGGACTGGGGGCGGG 535	
Sbjct	1751837	GGGACTGGGGGCGGG 1751851	